Sandra Lombardo, MD
Medical Oncology · Las Vegas, NVNPI 1235202516
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.8%), food and beverage and education — rather than concentrated in one kind of arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 15.9%. Reporting peaked in 2024 at $4,026 and has fallen 90.2% since, to $396 in 2025.
Across 183 payments — averaging $79.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$2K
- Boehringer Ingelheim$2K
- Beigene USA, Inc.$2K
- Astellas Pharma US Inc$1K
- Exelixis Inc.$942
- Bayer$932
- plus $6K from 34 others
What the payments were for
- Consulting fees$7,22550%
- Speaking & faculty fees$9256%
- Travel & lodging$2862%
- Food & beverage$3,44224%
- Education$2,61618%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 1 | $2,300 |
| Boehringer Ingelheim | 9 | $1,666 |
| Beigene USA, Inc. | 1 | $1,650 |
| Astellas Pharma US Inc | 18 | $1,371 |
| Exelixis Inc. | 2 | $942 |
| Bayer | 2 | $932 |
| AstraZeneca | 8 | $648 |
| GSK | 5 | $643 |
| Johnson & Johnson | 16 | $637 |
| Seagen Inc. | 12 | $558 |
| Bristol Myers Squibb | 17 | $285 |
| AbbVie | 7 | $275 |
| Mirati Therapeutics, Inc. | 5 | $257 |
| Eisai Inc. | 10 | $207 |
| Lilly USA, LLC | 6 | $205 |
| Merck | 8 | $184 |
| Stemline Therapeutics Inc. | 2 | $150 |
| Regeneron Healthcare Solutions, Inc. | 5 | $146 |
| Incyte Corporation | 4 | $144 |
| Dova Pharmaceuticals | 1 | $125 |
| Genentech USA, Inc. | 4 | $125 |
| Servier Pharmaceuticals LLC | 5 | $118 |
| Amgen | 3 | $113 |
| Jazz Pharmaceuticals Inc. | 3 | $102 |
| Sanofi-aventis U.S. LLC | 1 | $98 |
| Gilead | 4 | $91 |
| E.r. Squibb & Sons, L.L.C. | 4 | $89 |
| Pfizer | 3 | $59 |
| Novartis | 2 | $54 |
| AVEO Pharmaceuticals, Inc. | 2 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
| Karyopharm Therapeutics Inc. | 2 | $39 |
| Sanofi | 1 | $34 |
| Geron Corporation | 1 | $29 |
| Progenics Pharmaceuticals, Inc. | 1 | $24 |
| Coherus Oncology, Inc. | 1 | $22 |
| AMAG Pharmaceuticals, Inc. | 1 | $19 |
| Sobi, Inc | 1 | $17 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Janssen Scientific Affairs, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few medical oncology providers in Nevadato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 74 | $1,325,412 |
| IbrancePalbociclib | 48 | $787,069 |
| Lenalidomide | 37 | $539,540 |
| ErleadaApalutamide | 22 | $339,371 |
| JakafiRuxolitinib Phosphate | 17 | $269,126 |
| ImbruvicaIbrutinib | 12 | $194,842 |
| BrukinsaZanubrutinib | 12 | $149,054 |
| Abiraterone Acetate | 35 | $62,927 |
| CreonLipase/Protease/Amylase | 16 | $59,586 |
| XareltoRivaroxaban | 44 | $35,735 |
| EliquisApixaban | 14 | $20,187 |
| Letrozole | 201 | $3,650 |
| Exemestane | 35 | $3,241 |
| Imatinib Mesylate | 14 | $2,908 |
| Anastrozole | 143 | $2,517 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $285 | $1,325,41274 claims |
| PfizerIbrance, Eliquis | $59 | $807,25562 claims |
| Johnson & JohnsonErleada, Xarelto | $637 | $375,10666 claims |
| Incyte CorporationJakafi | $144 | $269,12617 claims |
| Beigene USA, Inc.Brukinsa | $1,650 | $149,05412 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $14 | $62,92735 claims |
| AbbVieCreon | $275 | $59,58616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical oncology providers in Nevadaon file to place this against a meaningful peer group, so we don't.
Other medical oncology in Las Vegas
- Fadi BraitehLas Vegas$2.7M
- Brian VicunaLas Vegas$107K
- Steven YatesLas Vegas$3K
- Deepa MocherlaLas Vegas$3K
- Claire HilesLas Vegas$918
- Okechukwu ObiLas Vegas$812
- Behrooz ShamlooLas Vegas$553
- Stephen IacoboniLas Vegas$477
- Swetha PentapatiLas Vegas$258
- Gary PalmerLas Vegas$86
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.